NCT00057239

An 8 Week Depression Study In Adults Diagnosed With Major Depressive Disorder

A Multi-Center, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy, Safety and Tolerability of Two Doses (20mg and 60mg) of a Once-Daily Oral Formulation of GW353162 in Subjects With Major Depressive Disorder for a Treatment Period of Eight Weeks

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 546 (planned)
• Sponsor: GlaxoSmithKline · Industry
• Sex: All
• Age: 18 Years – 64 Years
• Healthy volunteers: Not accepted

Summary

A Placebo Controlled Study Evaluating Efficacy, Safety and Tolerability of Radafaxine in Patients with Major Depressive Disorder (MDD)

Conditions

• Major Depressive Disorder (MDD)

Interventions

Type	Name	Description
DRUG	Radafaxine

Timeline

• Start date: 2003-03-01
• Primary completion: 2004-05-01
• Completion: 2004-05-01
• First posted: 2003-03-28
• Last updated: 2010-10-04

Locations

29 sites across 1 country: United States